p53, c-erbB2, and PCNA status in benign, proliferative, and malignant ovarian surface epithelial neoplasms. A study of 75 cases

Archives of Pathology and Laboratory Medicine

Volumn 123, Issue 4, 1999, Pages 310-316

  Anreder, Michael B ^a   Freeman, Scott M ^b   Merogi, Athir ^c   Halabi, Susan ^b   Marrogi, Aizen J ^d,e  

^a Department of Pathology   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARBOR HOSPITAL   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; MONOCLONAL ANTIBODY; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE C ERB; OVARY ADENOCARCINOMA; OVARY CARCINOMA;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032952571     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Kaern J, Tropé CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970-1982. Cancer. 1992;71:1810-1820.
2. Russell P. Surface epithelial-stromal tumors of the ovary. In: Kurman R, ed. Blaustein's Pathology of the Female Genital Tract. New York, NY: Springer-Verlag; 1994:706-713.
3. Berchuck A, Kohler MF, Hopkins MP. Over-expression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol. 1994;52:232-236.
4. Teneriello MG, Ebina M, Linnoila RI, et al. P53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 1993;53:3103-3108.
5. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol. 1993;12:120-127.